We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| SpringWorks Therapeutics Inc | NASDAQ:SWTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.52 | 1.22% | 42.98 | 41.34 | 46.42 | 43.01 | 41.86 | 42.20 | 553,169 | 23:11:53 |
From Nov 2023 to May 2024
By Dean Seal
Shares of SpringWorks were higher after the company received regulatory approval for its treatment of desmoid tumors.
The stock was up 11% at $23.01 in premarket trading. Shares had fallen 20% year-to-date when the market closed Monday.
The Stamford, Conn.-based biopharmaceutical company said after the bell on Monday that the U.S. Food and Drug Administration has approved Ogsiveo for adults with progressing desmoid tumors who require systemic treatment.
SpringWorks said Ogsiveo was the first FDA-approved therapy for patients with desmoid tumors.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 28, 2023 07:38 ET (12:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year SpringWorks Therapeutics Chart |
1 Month SpringWorks Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
